Overview

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

Status:
Active, not recruiting

Trial end date:
2022-02-09

Target enrollment:

Participant gender:

Summary

This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G ≥3, moderate or severe). Approximately 286 subjects with moderate to severe genital psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen
Celgene

Treatments:

Apremilast
Thalidomide